Transparency data

Research and methodology group

Updated 10 January 2024

This register records declarations made by members in respect of interests they have that are relevant to the remit of the UK NSC’s research and methodology group (RMG).

Dr Ania Bobrowska

• employed by Costello Medical, a consultancy that has delivered projects in evidence synthesis and the analysis, interpretation and communication of clinical and health economic data for the UK NSC
• listed on a grant for Policy Support Fund at University of Warwick on a methodology project with the aim ‘to redesign the methods used by the UK National Screening Committee when evaluating new screening tests using surrogate outcomes’ (Costello Medical is paid for Dr Bobrowska’s time (0.5 day per week) to work on the project)

Dr Adam Brentnall

• employed by King’s College London Cancer Prevention Trials Unit for consultancy related to developing and supporting an algorithm to invite people to the NHS Galleri Trial through NHS DigiTrials (indirect income from Grail through King’s)
• royalty payments through Cancer Research UK for commercial use of the IBIS (Tyrer-Cuzick) breast cancer risk algorithm
• employed by Queen Mary University of London
• research funding from Cancer Research UK (CRUK), Prostate Cancer UK, National Institute of Health Research (NIHR), Breast Cancer Now and Barts Charity
• genetic epidemiologist/statistician on the National Institute for Health and Care Excellence (NICE) familial ovarian cancer guideline committee
• standing member of Cancer Research UK’s expert review panel on early detection and diagnosis trials, behavioural, health systems and health economics research
• research in a variety of areas related to cancer screening and prevention, including:
  • investigating the effectiveness of gene testing for breast and ovarian cancer prevention
  • risk-stratified breast cancer screening
  • artificial intelligence (AI) methods for breast cancer screening
  • prostate cancer detection AI methods
  • multi-cancer early detection tests
  • molecular triage tests for HPV screening
  • alternative methods for HPV sampling
• as principal investigator (PI) or co-PI, engaged with others working in cancer screening and prevention, including those who sell breast density software (Volpara), genetic testing (Myriad Genetics), multi-cancer early detection tests (Grail), academics at other research institutions and colleagues who aim to develop biomarker panels for use in cancer screening, including in the molecular epidemiology laboratory at the Wolfson Institute of Population Health, Queen Mary University of London

Prof Karla Hemming

• none

Prof Joan Morris

• none

Dr Jason Oke

• advise and work on projects that are funded by organisations including the NIHR and CRUK and commercial organisations such as the National Consortium of Intelligent Medical Imaging (NCIMI) and Neuro-bio Ltd
• co-applicant on a grant proposal being submitted to NIHR looking at the evaluation of using AI in breast screening
• co-applicant on a grant proposal being submitted to NIHR looking at the evaluation of including a choice between self-sampling and current screening programme for cervical screening
• co-applicant on a grant proposal being submitted to CRUK to develop a core model for use in the evaluation of lung screening programmes.

Prof Katherine Payne

• member of Cancer Research UK Early Detection and Diagnosis Research Committee

Dr Jo Waller

• undertakes research funded by various charities and commercial organisations, currently including CRUK, Breast Cancer Now, Office for Health Improvement and Disparities, Grail Bio Ltd and the NHS Accelerated Access Collaborate (this funding is awarded to King’s College London)